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Abstract 
Background: Anti-N-methyl-d-aspartate receptor (NMDA-R) encephalitis is a recently identified but increasingly 
recognized autoimmune paraneoplastic disease. Because these patients present complex neuropsychiatric symptoms 
due to NMDA-R dysfunction, the optimal methods of sedation/anesthesia remain controversial. Here, we present 
animal experiment data, along with a related case report, implying the safe and effective use of dexmedetomidine in 
patients with anti-NMDA-R encephalitis.
Findings: (1) Animal experiment: in order to investigate whether dexmedetomidine may interfere with NMDA-R 
activity, an NMDA antagonist (MK-801) model in rats was used to simulate anti-NMDA-R encephalitis. Administration 
of MK-801 produced well-characterized schizophrenia-like behaviors, i.e. hyperlocomotion and stereotyped sniffing. 
Ketamine, an NMDA receptor-dependent anesthetic, exaggerated both behaviors, even at sub-anesthetic doses. On 
the other hand, dexmedetomidine did not show any exacerbation, suggesting that dexmedetomidine has no clini-
cally relevant interaction with the NMDA-R in vivo. (2) Case report: our patient, a 27-year-old female, was diagnosed 
with anti-NMDA-R encephalitis secondary to ovarian teratoma. She underwent laparoscopic ovariectomy under 
general anesthesia using thiopental, sevoflurane, and remifentanil, which were well tolerated. After transfer to the 
intensive care unit, she became increasingly agitated despite repeated boluses of intravenous fentanyl. Infusion of 
dexmedetomidine (0.5–1.0 μg/kg/h) was started, and an adequate level of sedation was achieved uneventfully. After 
discontinuation of dexmedetomidine, recovery from sedation was smooth and quick without any deterioration of 
neurological or psychological symptoms.
Conclusions: Our experimental findings and the presented case suggest that dexmedetomidine may be safely used 
in patients with anti-NMDA-R encephalitis. Further clinical evaluation is warranted to validate this finding.
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Background
Anti-N-methyl-d-aspartate receptor (NMDA-R) enceph-
alitis is an autoimmune disease first described in 2007 
(Dalmau et  al. 2011; Peery et  al. 2012; Titulaer et  al. 
2013). It has since been increasingly recognized as one 
of the more common identifiable causes of encepha-
litis. These patients typically present with neuropsy-
chiatric syndromes, including cognitive impairment, 
seizures, loss of consciousness, central hypoventilation, 
and autonomic nerve dysfunction. Its development is 
driven by an autoimmune reaction primarily against the 
NMDA-R. Anti-NMDA-R encephalitis is frequently a 
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paraneoplastic syndrome; a recent multi-institutional 
observational study has shown that 38 % of patients have 
presence of a tumor, of which 94 % were ovarian terato-
mas (Dalmau et  al. 2011). Initial therapy includes high-
dose steroids, immunoglobulin, and plasma exchange, 
as well as removal of any causative neoplasm if present. 
Therefore, during the acute phase, most patients may 
undergo a surgical procedure and intensive care support, 
thus requiring general anesthesia and sedation. However, 
the optimal anesthetics/sedation methods for patients 
with anti-NMDA-R encephalitis remain to be established 
(Pryzbylkowski et  al. 2011; Kawano et  al. 2011; Lapébie 
et al. 2014; Broderick et al. 2014; Simon 2014).
The NMDA-Rs play a crucial role in controlling synap-
tic plasticity and memory function (Paoletti et al. 2013). 
The functional NMDA-R is composed of both the NR1 
and NR2 subunits. The development of anti-NMDA-R 
encephalitis is associated with antibodies against NR1/
NR2 heteromers, which reduce NMDA-R density by an 
increase in receptor movement into the plasma mem-
brane, i.e., internalization (Hughes et al. 2010; van Coe-
vorden-Hameete et  al. 2014). The NMDA-Rs are also 
considered to be an important target of the most fre-
quently used inhaled and non-inhaled anesthetics that 
inhibit its functions (Franks 2008). Therefore, sedative/
anesthetic agents that act via antagonism of the NMDA-
R may potentially aggravate the disease symptoms (Pryz-
bylkowski et al. 2011; Simon 2014).
Dexmedetomidine is now widely used to provide seda-
tion, analgesia, and anti-sympathetic effects without 
respiratory depression during the perioperative period 
(Carollo et al. 2008). Additionally, recent studies suggest 
that dexmedetomidine exerts neuroprotective effects 
against brain injury in the central nervous system (Ma 
et  al. 2004; Degos et  al. 2013). The major sedative and 
antinociceptive effects of dexmedetomidine are due to 
its stimulation of α2-adrenoceptors located in the locus 
coeruleus (Hunter et  al. 1997). Therefore, dexmedeto-
midine may be suitable for postoperative sedation of 
patients with anti-NMDA-R encephalitis. However, the 
interaction between dexmedetomidine and NMDA-R 
activity remains under investigation, and there have been 
no reports on the clinical use of dexmedetomidine in the 
patients with anti-NMDA-R encephalitis.
In this report, we present experimental data regarding 
the use of dexmedetomidine under simulated NMDA-R 
hypo-functions in rats and a clinical case of anti-NMDA-
R encephalitis successfully sedated with dexmedetomi-
dine postoperatively.
Animal experiments
It is well reported that antagonists of the NMDA-R, such 
as phencyclidine, produce symptoms similar to those 
observed in patients with anti-NMDA-R encephalitis 
(Dalmau et al. 2011). Furthermore, an NMDA-R antago-
nist, MK-801, induces schizophrenia-like symptoms and 
is widely used as a rodent model of schizophrenia (And-
iné et al. 1999). Using this animal model, we investigated 
whether dexmedetomidine can be safely used under 
NMDA-R-deficient conditions, a mimic of anti-NMDA-R 
encephalitis.
All procedures were approved by the Kochi Univer-
sity Animal Experiment Committee. For the rat model of 
psychosis, male Sprague–Dawley rats (6 weeks old, body 
weight: 145–180  g) were intraperitoneally (i.p.) injected 
with MK-801 (Sigma-Aldrich, St. Louis, MO). Injections 
of 0.01, 0.02, or 0.05 mg/kg dexmedetomidine (n = 8 for 
each dose) were tested in this study. The NMDA-R antag-
onist anesthetic, ketamine, was used as a positive control 
at doses of 10, 50, and 100 mg/kg (n = 2–8, as indicated 
in Results).
On the day of the experiment, animals were 
placed inside a transparent Plexiglas chamber 
(45 × 45 × 40 cm). All animals were individually habitu-
ated in the test environment for at least 2 h prior to the 
test. MK-801 (0.1 mg/kg dissolved in 0.9 % saline) or an 
equal volume of saline was administered i.p., followed 
by a behavioral observation and rating procedure that 
started 15  min after the injection and continued for 
60  min. Two types of behavior, locomotor activity and 
stereotyped behavior, which are well-characterized com-
ponents associated with NMDA-R antagonism (Andiné 
et  al. 1999), were assessed by an observer blind to drug 
treatment. Locomotor activity was measured using pairs 
of 16 photo beams positioned 10  cm apart and 5  cm 
from the floor of the cage (Fig.  1). The total count of 
horizontal beam crosses was recorded every 5  min. For 
stereotyped sniffing rating, animals received a score of 
0 (absence), 1 (some rare), 2 (discontinuous, free inter-
val of more than 5 s), or 3 (continuous), according to the 
method described previously (Sukhanov et al. 2014). The 
rating procedure consisted of observation for 30 s every 
5 min. The results are presented as the mean ± standard 
error of the mean (SEM). Data were analyzed by two-way 
ANOVA repeated measures, followed by Bonferroni’s 
post hoc test. A p value of 0.05 was considered statisti-
cally significant.
As with previous reports (Andiné et  al. 1999), acute 
administration of MK-801 induced hyperlocomotion 
(Fig. 2a) and stereotypic sniffing (Fig. 2b), compared with 
control rats (p < 0.05, main effect of group for each varia-
ble). Sub-anesthetic doses of ketamine (10 and 50 mg/kg) 
dose-dependently exaggerated MK-801-induced hyperlo-
comotion (Fig. 3a) and stereotypic sniffing (Fig. 3b; both 
p < 0.05). For the anesthetic dose of ketamine (100 mg/
kg), the first two rats tested transiently developed 
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seizure-like movement, preventing appropriate behav-
ioral assessment, and subsequent investigation at this 
dose was discontinued. These results offer preclinical 
proof-of-concept that NMDA-R antagonist anesthetics, 
such as ketamine and N2O, should be avoided in patients 
with anti-NMDA-R encephalitis, due to possible further 
deterioration of NMDA-R hypofunction. On the other 
hand, sub-sedative doses of dexmedetomidine (0.01 and 
0.02 mg/kg) had no influence on MK-801-induced hyper-
locomotion (Fig.  4a) and stereotypic sniffing (Fig.  4b). 
Furthermore, the sedative dose of dexmedetomidine 
(0.05 mg/kg) significantly attenuated both behaviors; this 
may have been associated with its sedative effect.
Case report
A 27-year-old female with neither a history of psychiatric 
disorder nor mental retardation presented to her district 
general hospital with a 2-week history of headache, fever, 
slurred speech, and confused thinking. A timeline of the 
patient’s symptom trajectory is provided in Fig.  5. An 
electroencephalogram showed generalized non-specific 
slowing, and brain CT and MRI were normal. She was 
initially treated with acyclovir for possible viral enceph-
alitis due to herpes simplex virus (HSV). However, the 
patient did not respond to the treatment, and developed 
progressive confusion, short-term memory dysfunction, 
and partial complex seizures 6  weeks later. To manage 
these symptoms, a single dose of midazolam (5 mg, IV) 
was administered, but the patient subsequently devel-
oped coma with a Glasgow coma score of 5 (eye open-
ing 1, motor response 3, verbal response 1), and stayed 
unconscious for 3  days. During this period, the patient 
required tracheotomy and artificial ventilation. Repeated 
brain imaging was normal; however, anti-NMDA-R anti-
bodies, but not HSV DNA, were detected in the cerebro-
spinal fluid. Subsequent lower abdominal MRI revealed a 
3.5-cm left ovarian tumor, and the patient was diagnosed 
with anti-NMDA-R encephalitis. She was treated with 
plasma exchange followed by intravenous immunoglob-
ulin without improvement, and was then transferred to 
our hospital for laparoscopic ovariectomy.
On the day of surgery, the patient underwent general 
anesthesia with endotracheal intubation, consisting of 
induction with thiopental, fentanyl, and rocuronium, fol-
lowed by maintenance with sevoflurane (1.5–2.0 %) and 
Fig. 1 Picture of a rat during open-field test
Fig. 2 Time course of MK-801- or vehicle-induced locomotor activity (a) and stereotyped behavior (b). Each parameter was scored at baseline 
and at 5-min intervals starting 15 min after drug injection, and continued for 60 min. Each vertical bar represents the mean ± SEM (n = 8 in each 
experimental group)
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remifentanil infusion. Surgery was uneventful and com-
pleted in 84  min, and the pathology confirmed mature 
teratoma. Consistent with a previous case report in Japan 
(Kawano et  al. 2011), our case demonstrated that sevo-
flurane could maintain anesthesia without complication. 
Seven minutes after discontinuation of sevoflurane at 
the end of surgery, responses to verbal commands and 
spontaneous respiration via the tracheostomy cannula 
were observed, and she was transferred to the intensive 
care unit (ICU). However, the patient condition wors-
ened with agitated, oral-lingual-facial dyskinesia, limb 
dystonia, as well as developed tachycardia and hyperten-
sion. Analgesia was attempted with repeated boluses of 
50 µg fentanyl (total of 4 times), but failed to improve her 
symptoms. Dexmedetomidine was then infused at 1.0 μg/
kg/h for the first hour, followed by maintenance infusion 
Fig. 3 Effects of ketamine on MK-801-induced locomotor activity (a) stereotyped behavior (b). Each parameter was scored at baseline and at 
10-min intervals starting 15 min after drug injection, and continued for 60 min after injection of either MK-801 alone or combined with ketamine 
(10 or 50 mg/kg). Each vertical bar represents the mean ± SEM (n = 8 in each experimental group)
Fig. 4 Effects of dexmedetomidine on MK-801-induced locomotor activity (a) stereotyped behavior (b). Each parameter was scored at baseline and 
at 10-min intervals starting 15 min after drug injection, and continued for 60 min after injection of either MK-801 alone or combined with dexme-
detomidine (0.01, 0.02, or 0.05 mg/kg). Each vertical bar represents the mean ± SEM (n = 8 in each experimental group)
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of 0.5 μg/kg/h. In this case, we chose to avoid the load-
ing dose of dexmedetomidine to prevent any potential 
side-effects such as hypertension. An adequate level of 
sedation (Ramsay sedation score ≥3) was achieved with-
out supplemental sedatives or analgesics. Upon sedation, 
hemodynamics and arterial blood gasses were stabilized. 
The day after surgery, the patient was responsive to ver-
bal stimuli 15  min after discontinuation of dexmedeto-
midine infusion. The following postoperative course was 
uncomplicated, and she was discharged from the ICU on 
postoperative day 3. The patient showed steady clinical 
improvement, and was discharged from the hospital on 
postoperative day 51, with near complete recovery to her 
premorbid state.
Discussion
Anti-NMDA receptor encephalitis is now thought to 
be caused by the disruption of NMDA function by anti-
NMDA autoantibodies (Dalmau et  al. 2011; Peery et  al. 
2012; Titulaer et  al. 2013). It is frequently a paraneo-
plastic syndrome and surgical removal of tumor is asso-
ciated with better outcomes. Since the most common 
used anesthetics/sedatives interact with NMDA recep-
tor, it’s suspected that these anesthetics/sedatives leads to 
worsen the disease symptoms. More recent case reports 
indicated that general anesthesia with propofol or sevo-
flurane may be well tolerated (Pryzbylkowski et al. 2011; 
Kawano et al. 2011; Lapébie et al. 2014; Broderick et al. 
2014; Simon 2014). On the other hand, there have been 
no reports concerning postoperative intensive care seda-
tion of patients with anti-NMDA-R encephalitis. In this 
report, we first described a single case showing that dex-
medetomidine may contribute to improve the symptoms 
of anti-NMDA-R encephalitis exaggerated after surgery 
while we cannot rule out the possibility that this symp-
toms were also associated with postoperative delirium. 
Nevertheless, our findings imply that dexmedetomidine 
is safe and suitable for postoperative sedation, and 
allows stable hemodynamic responses in patients with 
anti-NMDA-R encephalitis.
The data of animal experiment suggest that dexme-
detomidine has no clinically relevant interaction with 
the NMDA-R in  vivo. These results may provide mech-
anistic support for the present case, i.e., a sedative dose 
of dexmedetomidine may be safely used in patients with 
anti-NMDA-R encephalitis. In addition, the sedative 
dose of dexmedetomidine could attenuated MK-801-in-
duced psychotic behavior (Fig.  4a, b). Consistent with 
our observations, it has been reported that clonidine, 
another clinically available α2 adrenergic agonist, could 
protect against MK-801-induced neurotoxicity (vacuole 
reaction) in rat retrosplenial cortex (Farber et  al. 2002). 
Furthermore, the most significant side-effects of dexme-
detomidine are hypotension and bradycardia (Carollo 
et al. 2008). However, these were not observed in the pre-
sent case, and postoperative autonomic hyperactivity as 
well as confusion could be controlled. Taking all together, 
our findings suggest dexmedetomidine may be a better 
choice for patients with anti-NMDA-R encephalitis. Nev-
ertheless, it is difficult to determine whether these effects 
were a direct pharmacological interaction of the dexme-
detomidine or a secondary result of sedation. Therefore, 
further clinical studies including case studies and treat-
ment experience are necessary to confirm this point of 
view.
In addition to dexmedetomidine, sedatives commonly 
used in the ICU include propofol and benzodiazepines. 
Propofol predominantly acts via direct activation of 
γ-aminobutyric acid (GABA) receptors, but also weakly 
inhibits NMDA-R (Lapébie et  al. 2014; Simon 2014). 
There has been one case report of a worsening of neu-
ropsychiatric symptoms including dyskinesias and 
tonic–clonic generalized seizure, while no adverse conse-
quences occurred during its intra-operative use (Lapébie 
Fig. 5 The patient’s trajectory of symptom presentation
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et  al. 2014). Further research is needed to determine 
what effects, if any, propofol administration may have 
on the symptoms of anti-NMDA-R encephalitis. Benzo-
diazepines bind to specific sites on postsynaptic GABA 
receptors, and can help manage agitation and insomnia 
associated with anti-NMDA-R encephalitis (Kruse et  al. 
2014). However, although it is unknown whether benzo-
diazepines were responsible for this unexpected serious 
coma in the present case, sustained consciousness dis-
turbance was observed after a one single sedative dose 
of i.v. midazolam, a short-acting benzodiazepine. Ben-
zodiazepines are metabolized by hepatic microsomal 
cytochrome P450 (CYP) enzymes, specifically CYP3A4 
(Olkkola and Ahonen 2008). Therefore, we cannot rule 
out the possibility that our patient was a CYP3A4 poor 
metabolizer, resulting in increased plasma concentra-
tions of midazolam.
In conclusion, we report for the first time success-
ful management of a case of anti-NMDA-R encephalitis 
with intravenous dexmedetomidine infusion for post-
operative intensive care sedation. Preclinical data using 
a rat model also suggested that clinically relevant doses 
of dexmedetomidine had no noticeable effects on neuro-
logical or psychiatric symptoms associated with NMDA-
R dysfunction. Our findings imply that dexmedetomidine 
can be safely used as a sedative agent for patients with 
anti-NMDA-R encephalitis.
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